Latest news for Gaensel Energy Group (OTC:GEGR) Stock

Gaensel Energy Group Inc is a diversified holding company with assets in Software/Gaming and VR, Health and Wellness, Technology, CRM and Data, Commodities, Retail Coffee, as well as Renewable Energy and Contracting.

GAENSEL ENERGY GROUP INC by Gaensel Energy Group, Inc.

Gaensel Energy Group Inc

The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/KO/earnings">opening bell, on Tuesday, Feb. 11, 2025.</a>
Analysts expect the Atlanta-based company to report quarterly earnings at 52 cents per share, up from 49 cents per share in the year-ago period. Coca-Cola projects quarterly revenue of $10.7 billion, compared to $10.95 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 30, Jefferies analyst Kaumil Gajrawala upgraded Coca-Cola from Hold to Buy and raised the price target from $69 to $75.
With the recent buzz around Coca-Cola, some investors may be eyeing potential gains from the company's dividends too. As of now, Coca-Cola offers an annual dividend yield of 3.04%, which is a quarterly dividend amount of 48 cents per share ($1.94 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $197,457 or around 3,093 shares. For a more modest $100 per month or $1,200 per year, you would need $39,517 or around 619 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.94 in this case). So, $6,000 / $1.94 = 3,093 ($500 per month), and $1,200 / $1.94 = 619 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
Price Action: Shares of Coca-Cola gained 0.8% to close at $63.84 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a></li>
</ul>

Earnings

Long Ideas

News

Markets

How To Earn $500 A Month From Coca-Cola Stock Ahead Of Q4 Earnings

Barclays analyst Tim Long maintains Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) with a Underweight and lowers the price target from $236 to $222.

Price Target

Analyst Ratings

Barclays Maintains Underweight on Ubiquiti, Lowers Price Target to $222

Kelleher to help drive Okta's growth through operational excellence in new role; Eugenio Pace to retire from role as President, Business Operations
Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), the leading independent identity partner, today announced the appointment of Eric Kelleher as President and Chief Operating Officer (COO). In this new role, Kelleher will continue to report to CEO and co-founder Todd McKinnon. He will now oversee Okta's Marketing, Customer First, Company Operations, GTM Strategy &amp; Operations, Business Technology, Data &amp; Insights, Communications, and Okta for Good teams.
In addition, Eugenio Pace, Okta's President, Business Operations, has decided to retire at the end of March 2025 after nearly four years of exceptional leadership at Okta following the company's acquisition of Auth0.

Management

OKTA

Okta Appoints Eric Kelleher As President And Chief Operating Officer

Keybanc analyst Alex Markgraff maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Overweight and raises the price target from $140 to $142.

Keybanc Maintains Overweight on Trade Desk, Raises Price Target to $142

WIIM

MBLY

Mobileye Global shares are trading higher after B of A Securities upgraded the stock from Underperform to Neutral and raised its price target from $12 to $19.

Biotech

General

BCRX

Biocryst Pharmaceuticals Announces The Company Will Present Five Abstracts Featuring New Clinical And Real-World Outcomes With Oral, Once-Daily Orladeyo For The Prophylactic Treatment Of Hereditary Angioedema At The 2025 American Academy Of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress.

Barclays analyst Andrew Lazar maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Equal-Weight and lowers the price target from $170 to $160.

Barclays Maintains Equal-Weight on Hershey, Lowers Price Target to $160

UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic's Specialty Diagnostic Suite
GeneDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), a leader in delivering improved health outcomes through genomic insights, announced today its launch on Aura, Epic's specialty diagnostics suite, offering advance genetic sequencing within health systems electronic health records (EHR) to receive orders and send results. GeneDx is expanding access to its industry leading diagnostic tests for health systems to deliver fast and accurate genetic diagnoses to patients and accelerate the path to treatment, with UNC Health becoming the first health system to integrate with GeneDx through Aura. Effective today, additional health systems can connect via Aura to order GeneDx's tests including exome sequencing (ES), whole genome sequencing (WGS) and rapid whole genome sequencing (rWGS).

GeneDx Announces Its Launch On Aura, Epic's Specialty Diagnostics Suite, Offering Advance Genetic Sequencing Within Health Systems Electronic Health Records To Receive Orders And Send Results

Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock is trading lower on Monday.
On Friday, during after-hours trading, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43574512/pliant-therapeutics-provides-update-on-beacon-ipf-a-phase-2b3-trial-in-patients-with-idiopathic-pu" rel="noreferrer noopener">idiopathic pulmonary fibrosis (IPF)</a>, a chronic lung disease that causes scarring and stiffening of the lung tissue.&nbsp;
Patients currently enrolled in BEACON-IPF will remain in the trial.
The move follows a prespecified data review and recommendations by the trial&#8217;s independent Data Safety Monitoring Board.
Enrollment and dosing have been paused while data are reviewed to understand the DSMB&#8217;s rationale for their recommendation. The study will be blinded to preserve trial integrity.
In May 2024, On Tuesday,&nbsp;Pliant Therapeutics announced topline data from a Phase 2a PET Imaging trial of&nbsp;bexotegrast&nbsp;(PLN-74809) evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF) characterized by excessive collagen&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38819267/pliant-therapeutics-drug-trial-shows-promise-in-reversing-lung-fibrosis-in-patients" rel="noreferrer noopener">deposition in the lung</a>.
Bexotegrast-treated patients showed reduced total lung collagen post-treatment as measured by positron emission tomography (PET) imaging, compared to increased total lung collagen in the placebo group, suggesting potential reversal of fibrosis.&nbsp;
Last February, Pliant Therapeutics released 12-week interim data from the 320 mg dose group of INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36937322/why-is-liver-disease-focused-pliant-therapeutics-stock-trading-lower-today" rel="noreferrer noopener">moderate to severe liver fibrosis</a>.&nbsp;
The 320 mg group met its primary and secondary endpoints, demonstrating that bexotegrast was well tolerated over a 12-week treatment period, and its plasma concentrations increased with dose.&nbsp;
There was no dose relationship for adverse events. Pruritus and cholangitis occurred less frequently on bexotegrast than on placebo.
Price Action: PLRX stock is down 64.10% at $2.80 during the premarket session at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43570574/netflix-eyes-formula-one-us-broadcast-rights-starting-in-2026-report" target="_blank" rel="noreferrer noopener">Netflix Eyes Formula One US Broadcast Rights Starting In 2026</a></li>
</ul>

Health Care

Movers

Trading Ideas

PLRX

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

Keybanc analyst Alex Markgraff maintains i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) with a Overweight and raises the price target from $27 to $32.

IIIV

Keybanc Maintains Overweight on i3 Verticals, Raises Price Target to $32

Barclays analyst Matt Miksic maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $418 to $443.

Barclays Maintains Overweight on Stryker, Raises Price Target to $443

Keybanc analyst Justin Patterson maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Overweight and raises the price target from $55 to $65.

GLBE

Keybanc Maintains Overweight on Global E Online, Raises Price Target to $65

Barclays analyst Adrienne Yih maintains Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) with a Overweight and lowers the price target from $80 to $77.

Barclays Maintains Overweight on Skechers USA, Lowers Price Target to $77

ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) released its Q4 earnings on Monday, February 10, 2025 at 07:30 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
ON Semiconductor missed estimated earnings by -2.0%, reporting an EPS of $0.95 versus an estimate of $0.97.
Revenue was down $295.00 million from the same period last year.
<h3>Earnings History Overview</h3>
The company beat on EPS by $0.02 in the previous quarter, leading to a 3.0% increase share price change the next day.
Here's a look at ON Semiconductor's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.97</td>
<td>0.92</td>
<td>1.04</td>
<td>1.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.99</td>
<td>0.96</td>
<td>1.08</td>
<td>1.25</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.75B</td>
<td>1.73B</td>
<td>1.85B</td>
<td>2.00B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.76B</td>
<td>1.74B</td>
<td>1.86B</td>
<td>2.02B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
ON Semiconductor management provided guidance for Q1 2025, expecting earnings between $0.45 and $0.55 per share.
To track all earnings releases for ON Semiconductor <a href="https://www.benzinga.com/quote/ON/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: ON Semiconductor Q4

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) with a Market Perform and raises the price target from $176 to $179.

Keefe, Bruyette & Woods Maintains Market Perform on Hanover Insurance Gr, Raises Price Target to $179

Keybanc analyst Matthew Gillmor maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Overweight and raises the price target from $117 to $120.

Keybanc Maintains Overweight on Encompass Health, Raises Price Target to $120

Barclays analyst Matthew Bouley maintains Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) with a Equal-Weight and lowers the price target from $130 to $125.

Barclays Maintains Equal-Weight on Mohawk Industries, Lowers Price Target to $125

Amazon.com Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) <a href="https://www.benzinga.com/quote/AMZN/earnings">latest earnings call</a> sent investors into a brief panic, with shares slipping 4% post-report. But was it really thesis-changing? 
JPMorgan's Doug Anmuth doesn't think so. The big talking point? 
Amazon Web Services&#8217; (AWS) growth trajectory and a single word from Amazon's scripted remarks: &#8220;lumpy.&#8221;
<h2 class="wp-block-heading">AWS &amp; AI: The Perfect Growth Catalyst?</h2>
Lumpy isn't usually a word that rattles Wall Street, but the Street heard &#8220;volatile&#8221; instead of &#8220;long-term upside.&#8221; AWS growth is expected to slow in early 2025 before accelerating in the second half, with CEO Andy Jassy assuring investors that supply constraints should ease. But that's contingent on Nvidia Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips, Trainium2, and a host of tech bottlenecks playing along. Anmuth remains optimistic, standing by an 18% AWS growth forecast for 1H25, ramping past 20% in 2H25 and beyond.
Read Also: <a href="https://www.benzinga.com/25/02/43570975/amazon-to-rally-over-20-here-are-10-top-analyst-forecasts-for-friday">Amazon To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Friday</a>
Meanwhile, Amazon's 2025 capex outlook of $105 billion—well above Street expectations—has some investors worried about free cash flow. But Anmuth argues that AI investments will pay off, likening Amazon's infrastructure push to the competitive advantages enjoyed by Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google.
If Jevons Paradox holds true, lower inference costs could actually boost AWS revenue, as customers deploy more AI-driven applications.
Beyond cloud, Amazon's international business faces macroeconomic headwinds, particularly in Germany where growth has decelerated. FX pressures and last year's leap day also complicate Q1 revenue comps. Still, Amazon's logistics efficiency continues to improve, with same-day delivery expansion and robotics-driven cost reductions providing a silver lining.
<h2 class="wp-block-heading">Investor Takeaway: Is Amazon Set For A Big Move?</h2>
So what's the bottom line? Anmuth sees Amazon as a multi-year winner in both e-commerce and cloud, even if the road ahead has some bumps. His $270 price target reflects confidence in Amazon's AI monetization and operating margin expansion. For long-term investors, the message is clear: ignore the lumps, follow the growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43577796/cathie-woods-ark-invest-bets-big-on-amazon-roblox-and-illumina-while-trimming-palantir-stake-after-alex-karp-led-company-touched-an-all-time-high-on-thursday">Cathie Wood&#8217;s Ark Invest Bets Big On Amazon, Roblox And Illumina While Trimming Palantir Stake</a></li>
</ul>

Analyst Color

Tech

AMZN

GOOG

GOOGL

NVDA

Amazon's AI Bet Is Big, But Will Investors Stick Around For The 'Lumps'?

Barclays analyst Michael Leithead maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Equal-Weight and raises the price target from $54 to $57.

MEOH

Barclays Maintains Equal-Weight on Methanex, Raises Price Target to $57

Keefe, Bruyette &amp; Woods analyst Michael Brown maintains Perella Weinberg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWP#NASDAQ">PWP</a>) with a Outperform and raises the price target from $27 to $29.

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

Comments

Gaensel Energy Group

News

Latest news for Gaensel Energy Group (OTC:GEGR) Stock

Monday, December 06, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga